AIM ImmunoTech Non-Current Deferred Revenue (Quarterly) Insights

AIM ImmunoTech, Inc. (AIM)

1.22 -0.07 (-5.43%) USD | NYAM | Jan 12, 12:32

View Non-Current Deferred Revenue (Quarterly) for AIM.
Upgrade now.

Sep '18

Jan '19

May '19

285.00

270.00

255.00

240.00

View Non-Current Deferred Revenue (Quarterly) Chart

Start Trial

View Historical Data

Start Trial

View Non-Current Deferred Revenue (Quarterly) Range, Past 5 Years

Start Trial

Minimum

Maximum

Average

Median

View Non-Current Deferred Revenue (Quarterly) Benchmarks

Start Trial

Halozyme Therapeutics, Inc.	--
Agenus, Inc.	Upgrade
Curis, Inc.	--
Protalix Biotherapeutics, Inc.	--
Armata Pharmaceuticals, Inc.	--